-- The Federal Trade Commission has opened an investigation into TevaPharmaceutical Industries over its patent practices, the Washington Postreported on Monday. -- The probe focuses on the Israeli company's refusal to withdraw patents forasthma inhalers and treatments for chronic obstructive pulmonarydisease from a federal registry called the Orange Book, according to the Post. -- The FTC claims Teva made small modifications to keep the patents in the registryand stifle competition, the Post reported. -- Teva spokesperson Kelley Dougherty told The Wall Street Journal that thecompany's patents are properly listed and that Teva "continues to standbehind the company's intellectual property." Full article at https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/Write to Victor Swezey at victor.swezey@wsj.com(END) Dow Jones NewswiresJuly 01, 2024 12:49 ET (16:49 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Washington Post July 01, 2024 17:23 UTC